Nothing Special   »   [go: up one dir, main page]

DK0729473T3 - Glucosamin-disaccharider, fremgangsmåde til deres fremstilling farmaceutisk sammensætning deraf og deres anvendelse - Google Patents

Glucosamin-disaccharider, fremgangsmåde til deres fremstilling farmaceutisk sammensætning deraf og deres anvendelse

Info

Publication number
DK0729473T3
DK0729473T3 DK95903265T DK95903265T DK0729473T3 DK 0729473 T3 DK0729473 T3 DK 0729473T3 DK 95903265 T DK95903265 T DK 95903265T DK 95903265 T DK95903265 T DK 95903265T DK 0729473 T3 DK0729473 T3 DK 0729473T3
Authority
DK
Denmark
Prior art keywords
disaccharides
pct
pharmaceutical composition
date
lipid
Prior art date
Application number
DK95903265T
Other languages
English (en)
Inventor
Pierre Hirt
Adrian Schulthess
John Gwynfor Davies
Jacques Bauer
Original Assignee
Deutsche Om Arzneimittel Gmbh
Om Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsche Om Arzneimittel Gmbh, Om Pharma filed Critical Deutsche Om Arzneimittel Gmbh
Application granted granted Critical
Publication of DK0729473T3 publication Critical patent/DK0729473T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • C07H13/06—Fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK95903265T 1993-11-17 1994-11-17 Glucosamin-disaccharider, fremgangsmåde til deres fremstilling farmaceutisk sammensætning deraf og deres anvendelse DK0729473T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP93203223 1993-11-17
PCT/EP1994/003852 WO1995014026A1 (en) 1993-11-17 1994-11-17 Glucosamine disaccharides, method for their preparation, pharmaceutical composition comprising same, and their use

Publications (1)

Publication Number Publication Date
DK0729473T3 true DK0729473T3 (da) 2000-10-30

Family

ID=8214175

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95903265T DK0729473T3 (da) 1993-11-17 1994-11-17 Glucosamin-disaccharider, fremgangsmåde til deres fremstilling farmaceutisk sammensætning deraf og deres anvendelse

Country Status (22)

Country Link
US (1) US6005099A (da)
EP (1) EP0729473B1 (da)
JP (1) JP3967769B2 (da)
KR (1) KR100355470B1 (da)
CN (1) CN1055093C (da)
AT (1) ATE195740T1 (da)
AU (1) AU700485B2 (da)
BR (1) BR9408071A (da)
CA (1) CA2175375C (da)
CZ (1) CZ290331B6 (da)
DE (1) DE69425671T2 (da)
DK (1) DK0729473T3 (da)
ES (1) ES2149340T3 (da)
GR (1) GR3034872T3 (da)
HU (1) HU219810B (da)
PL (1) PL181241B1 (da)
PT (1) PT729473E (da)
RO (1) RO115731B1 (da)
RU (1) RU2154068C2 (da)
SI (1) SI0729473T1 (da)
SK (1) SK281944B6 (da)
WO (1) WO1995014026A1 (da)

Families Citing this family (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1091928B1 (fr) * 1998-06-30 2007-02-28 OM Pharma Nouveaux pseudodipeptides acyles, leur mode de preparation et les compositions pharmaceutiques en renfermant
PL350032A1 (en) 1999-02-10 2002-10-21 Sankyo Co Ether type lipid a1-carboxylic acid analogues
EP2204186B1 (en) 1999-02-17 2016-04-06 CSL Limited Immunogenic complexes and methods relating thereto
WO2001036433A2 (en) * 1999-11-15 2001-05-25 Biomira, Inc. Synthetic lipid-a analogs and uses thereof
WO2001046127A1 (fr) * 1999-12-22 2001-06-28 Om Pharma Pseudodipeptides acyles porteurs d'un bras auxiliaire fonctionnalise
KR100898844B1 (ko) * 1999-12-22 2009-05-21 옴 파르마 작용기화된 보조 아암을 가진 아실 슈도디펩티드
DK2266603T3 (da) 2000-10-18 2012-11-05 Glaxosmithkline Biolog Sa Tumorvacciner
KR100465229B1 (ko) * 2001-04-09 2005-01-13 주식회사 안지오랩 2-아미노-2-데옥시-ｄ-글루코피라노오즈 또는 그의약학적으로 허용가능한 염을 유효성분으로 하는 혈관신생억제용 약학적 조성물
WO2004030608A2 (en) * 2001-06-05 2004-04-15 The Regents Of The University Of Michigan Nanoemulsion vaccines
PL376792A1 (pl) 2002-10-23 2006-01-09 Glaxosmithkline Biologicals S.A. Sposoby szczepienia przeciwko malarii
GB0321615D0 (en) 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
EP1755666B1 (en) 2004-05-28 2010-12-15 GlaxoSmithKline Biologicals SA Vaccine compositions comprising virosomes and a saponin adjuvant
WO2006095270A1 (en) * 2005-03-10 2006-09-14 Om Pharma Combination anticancer therapy or om-174 and pharmaceutical compositions therefor
AU2005266106B2 (en) * 2004-07-23 2010-12-09 Om Pharma Combination anticancer therapy and pharmaceutical compositions therefore
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
US20060210590A1 (en) 2005-02-03 2006-09-21 Alk-Abello A/S Minor allergen control to increase safety of immunotherapy
GB0503337D0 (en) 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
TW200722101A (en) 2005-03-23 2007-06-16 Glaxosmithkline Biolog Sa Novel composition
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
LT2384765T (lt) 2005-12-22 2017-01-10 Glaxosmithkline Biologicals S.A. Streptococcus pneumoniae vakcina
JP2009531387A (ja) 2006-03-30 2009-09-03 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
KR100780868B1 (ko) * 2006-07-10 2007-11-30 부경대학교 산학협력단 항암효과를 나타내는 4급 아미노 글루코사민 화합물
SI2043682T1 (sl) 2006-07-17 2014-07-31 Glaxosmithkline Biologicals S.A. Influenčno cepivo
AU2007276219B2 (en) 2006-07-18 2013-10-03 Glaxosmithkline Biologicals S.A. Vaccines for malaria
WO2008012538A2 (en) 2006-07-25 2008-01-31 The Secretary Of State For Defence Live vaccine strains of francisella
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
PL2468300T3 (pl) 2006-09-26 2018-04-30 Infectious Disease Research Institute Kompozycja szczepionki zawierająca syntetyczny adiuwant
PL2086582T3 (pl) 2006-10-12 2013-04-30 Glaxosmithkline Biologicals Sa Kompozycja zawierająca adiuwant w postaci emulsji typu olej w wodzie
WO2008059307A2 (en) * 2006-11-16 2008-05-22 Om Pharma Functionalized beta 1,6 glucosamine disaccharides and process for their preparation
CA2679410C (en) 2007-03-02 2017-01-17 Glaxosmithkline Biologicals S.A. Novel method and compositions
ES2665002T3 (es) 2007-03-05 2018-04-24 Om Pharma Extracto bacteriano para trastornos respiratorios y procedimiento para su preparación
US9452209B2 (en) 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
EA020817B1 (ru) 2007-06-26 2015-02-27 Глаксосмитклайн Байолоджикалс С.А. Вакцина, содержащая конъюгаты капсульных полисахаридов streptococcus pneumoniae
WO2009117035A1 (en) 2007-12-19 2009-09-24 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Soluble forms of hendra and nipah virus f glycoprotein and uses thereof
MX2010007107A (es) 2007-12-24 2010-12-21 Id Biomedical Corp Quebec Antigenos de virus del sincicio respiratorio recombinantes.
ES2553113T3 (es) 2008-04-16 2015-12-04 Glaxosmithkline Biologicals S.A. Vacuna
US20090291095A1 (en) * 2008-05-23 2009-11-26 The Regents Of The University Of Michigan Nanoemulsion adjuvants
EP2293813A4 (en) 2008-05-23 2012-07-11 Univ Michigan NANOEMULSION VACCINES
JP5775451B2 (ja) 2008-06-19 2015-09-09 バリエーション バイオテクノロジーズ インコーポレイティド インフルエンザを処置するための組成物および方法
JP5722782B2 (ja) * 2008-09-26 2015-05-27 ナノバイオ コーポレーション ナノエマルジョン治療用組成物及びその使用方法
CN102325790A (zh) 2008-12-03 2012-01-18 西马生物医学计划公司 应用酚可溶性调控蛋白研制疫苗
WO2010079081A1 (en) 2009-01-07 2010-07-15 Glaxosmithkline Biologicals S.A. Methods for recovering a virus or a viral antigen produced by cell culture
GB0901411D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
GB0901423D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
CA2750055A1 (en) 2009-02-06 2010-08-12 Glaxosmithkline Biologicals S.A. Method for purifying viruses using a density gradient
KR101738704B1 (ko) 2009-02-17 2017-06-08 글락소스미스클라인 바이오로지칼즈 에스.에이. 알루미늄-비함유 아주반트를 포함하는 불활성화 뎅기 바이러스 백신
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
US20110097418A1 (en) * 2009-05-29 2011-04-28 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
US8722064B2 (en) 2009-06-05 2014-05-13 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants
US20100316673A1 (en) * 2009-06-16 2010-12-16 The Regents Of The University Of Michigan Nanoemulsion vaccines
US8889146B2 (en) 2009-06-24 2014-11-18 Glaxosmithkline Biologicals, Sa Vaccine
EA023054B1 (ru) 2009-06-24 2016-04-29 Глэксосмитклайн Байолоджикалз С.А. Рекомбинантные антигены pcb
AU2010270722B2 (en) 2009-07-06 2015-06-04 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
US9907746B2 (en) 2009-07-06 2018-03-06 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
TW201116294A (en) 2009-07-15 2011-05-16 Novartis Ag RSV F protein compositions and methods for making same
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
CA2774555A1 (en) 2009-09-25 2011-03-31 Glaxosmithkline Biologicals S.A. Immunodiffusion assay for influenza virus
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
WO2011101332A1 (en) 2010-02-16 2011-08-25 Proyecto De Biomedicina Cima, S.L. Compositions based on the fibronectin extracellular domain a for the treatment of melanoma
WO2011116262A2 (en) * 2010-03-19 2011-09-22 The Regents Of The University Of Michigan Compositions and methods for diagnosing and treating urinary tract infections
JP6200805B2 (ja) 2010-05-03 2017-09-20 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規な方法
GB201009273D0 (en) 2010-06-03 2010-07-21 Glaxosmithkline Biolog Sa Novel vaccine
US8658603B2 (en) 2010-06-16 2014-02-25 The Regents Of The University Of Michigan Compositions and methods for inducing an immune response
CA2840079C (en) 2010-07-06 2018-07-03 Variation Biotechnologies Inc. Compositions and methods for treating influenza
MX354752B (es) 2010-09-27 2018-03-20 Janssen Vaccines & Prevention Bv Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria.
KR20130140009A (ko) 2010-10-15 2013-12-23 글락소스미스클라인 바이오로지칼즈 에스.에이. 사이토메갈로바이러스 ｇｂ 항원
WO2012097346A1 (en) 2011-01-13 2012-07-19 Variation Biotechnologies, Inc. Compositions and methods for treating viral infections
CN103533923A (zh) 2011-01-13 2014-01-22 变异生物技术公司 囊泡及由其产生之制剂的制备方法
EP2505640A1 (en) 2011-03-29 2012-10-03 Neo Virnatech, S.L. Vaccine compositions for birnavirus-borne diseases
AU2012243039B2 (en) 2011-04-08 2017-07-13 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
BR112013029514A2 (pt) 2011-05-17 2019-09-24 Glaxosmithkline Biologicals Sa composição imunogênica, vacina, e, método de tratar ou impedir uma doença
US10752676B2 (en) 2011-09-16 2020-08-25 Ucb Biopharma Sprl Neutralising antibodies to the major exotoxins TCDA and TCDB of Clostridium difficile
WO2013074501A1 (en) 2011-11-14 2013-05-23 Crucell Holland B.V. Heterologous prime-boost immunization using measles virus-based vaccines
EP2802353A4 (en) 2012-01-12 2015-12-02 Variation Biotechnologies Inc COMPOSITIONS AND METHOD FOR THE TREATMENT OF VIRUS INFECTIONS
RU2698906C2 (ru) 2012-01-27 2019-09-02 Вэриэйшн Биотекнолоджиз, Инк. Способы и композиции для терапевтических агентов
WO2013139744A1 (en) 2012-03-18 2013-09-26 Glaxosmithkline Biologicals S.A. Method of vaccination against human papillomavirus
US9518078B2 (en) * 2012-04-12 2016-12-13 Avanti Polar Lipids, Inc. Disaccharide synthetic lipid compounds and uses thereof
US9241988B2 (en) * 2012-04-12 2016-01-26 Avanti Polar Lipids, Inc. Disaccharide synthetic lipid compounds and uses thereof
ES2787455T3 (es) 2012-05-16 2020-10-16 Immune Design Corp Vacunas para el VHS-2
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
CA2879939A1 (en) 2012-08-06 2014-02-13 Glaxosmithkline Biologicals S.A. Novel method
WO2014160463A1 (en) 2013-03-13 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prefusion rsv f proteins and their use
US10058603B2 (en) 2013-03-15 2018-08-28 Glaxosmithkline Biologicals S.A. Vaccine
US8957047B2 (en) 2013-04-18 2015-02-17 Immune Design Corp. GLA monotherapy for use in cancer treatment
ES2828373T3 (es) 2013-06-04 2021-05-26 Aparin Petr Gennadievich Lipopolisacárido modificado (variantes) de bacterias endotóxicas, combinación de lipopolisacáridos modificados (variantes) y una vacuna (variantes), que los contiene, y una composición farmacéutica (variantes)
US11052142B2 (en) * 2013-06-04 2021-07-06 Petr G. Aparin Modified endotoxic bacteria lipopolysaccharide (variants), combination of modified lipopolysaccharides (variants) and, containing same, a vaccine (variants) and a pharmaceutical composition (variants)
US9463198B2 (en) * 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
JP6564367B2 (ja) 2013-08-05 2019-08-21 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 併用免疫原性組成物
CA2920934C (en) 2013-08-30 2022-12-06 Glaxosmithkline Biologicals S.A. Large scale production of viruses in cell culture
CN104436157A (zh) 2013-09-23 2015-03-25 恩金生物有限公司 流感疫苗和治疗
CA2928700C (en) 2013-11-01 2019-01-15 University Of Oslo Albumin variants and uses thereof
US11452767B2 (en) 2013-11-15 2022-09-27 Oslo Universitetssykehus Hf CTL peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof
WO2015092710A1 (en) 2013-12-19 2015-06-25 Glaxosmithkline Biologicals, S.A. Contralateral co-administration of vaccines
US10821175B2 (en) 2014-02-25 2020-11-03 Merck Sharp & Dohme Corp. Lipid nanoparticle vaccine adjuvants and antigen delivery systems
WO2015165480A1 (en) 2014-04-30 2015-11-05 Institute For Research In Biomedicine Human cytomegalovirus vaccine compositions and method of producing the same
EP3888676A1 (en) 2014-06-13 2021-10-06 GlaxoSmithKline Biologicals S.A. Immunogenic combinations
US11083788B2 (en) 2014-10-10 2021-08-10 The Regents Of The University Of Michigan Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease
WO2016140702A1 (en) 2015-03-03 2016-09-09 The United States Of America, As Represented By The Secretary, Department Of Health & Human Serivces Display platform from bacterial spore coat proteins
EP4226937A3 (en) 2015-03-05 2023-09-27 Northwestern University Non-neuroinvasive viruses and uses thereof
WO2016207730A1 (en) 2015-06-22 2016-12-29 The University Of Oslo Targeting of vaccine antigen to an intracellular compartment
EP3313435A1 (en) 2015-06-26 2018-05-02 Institute for Research in Biomedicine Novel vaccines in prevention and treatment of malaria
WO2017158421A1 (en) 2016-03-14 2017-09-21 University Of Oslo Anti-viral engineered immunoglobulins
MY195541A (en) 2016-03-14 2023-01-31 Univ Oslo Engineered Immunoglobulins With Altered Fcrn Binding
US11173207B2 (en) 2016-05-19 2021-11-16 The Regents Of The University Of Michigan Adjuvant compositions
EP3471761A2 (en) 2016-06-21 2019-04-24 University Of Oslo Hla binding vaccine moieties and uses thereof
BR112019003462A2 (pt) 2016-08-23 2019-06-25 Glaxosmithkline Biologicals Sa proteína de fusão, polinucleotídeo, vetor viral, composição farmacêutica, uso de uma proteína de fusão, polinucleotídeo, vetor viral ou composição farmacêutica, e, método para tratar ou prevenir infecção de hepatite b viral ou infecção de hepatite c viral
GB201614799D0 (en) 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions
BE1024774B1 (fr) 2016-09-29 2018-07-02 Glaxosmithkline Biologicals Sa Compositions et procedes de traitement
WO2018096396A1 (en) 2016-11-22 2018-05-31 University Of Oslo Albumin variants and uses thereof
GB201620968D0 (en) 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
US11084850B2 (en) 2016-12-16 2021-08-10 The Pirbright Institute Recombinant prefusion RSV F proteins and uses thereof
WO2018162450A1 (en) 2017-03-06 2018-09-13 Fundación Para La Investigación Médica Aplicada New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells
CN118085055A (zh) 2017-04-19 2024-05-28 生物医学研究所 作为疫苗及新疟疾疫苗和抗体结合靶标的疟原虫子孢子npdp肽
WO2018229708A1 (en) 2017-06-16 2018-12-20 Glaxosmithkline Biologicals Sa Method of treatment
EP3678698A1 (en) 2017-09-07 2020-07-15 University Of Oslo Vaccine molecules
EP3678699A1 (en) 2017-09-07 2020-07-15 University Of Oslo Vaccine molecules
WO2019051149A1 (en) 2017-09-08 2019-03-14 Infectious Disease Research Institute LIPOSOMAL FORMULATIONS COMPRISING SAPONIN AND METHODS OF USE
GB201721068D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B immunisation regimen and compositions
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
AU2019218978A1 (en) 2018-02-12 2020-09-03 Inimmune Corporation Toll-like receptor ligands
CA3102224A1 (en) 2018-06-12 2019-12-19 Glaxosmithkline Biologicals Sa Chimpanzee adenovirus chad157 polynucleotides, polypeptides.vectors, compositions, cells and uses thereof
EP3581201A1 (en) 2018-06-15 2019-12-18 GlaxoSmithKline Biologicals S.A. Escherichia coli o157:h7 proteins and uses thereof
BR112021000965A2 (pt) 2018-08-07 2021-04-27 Glaxosmithkline Biologicals S.A. processos e vacinas
US20220184158A1 (en) 2018-12-21 2022-06-16 Glaxosmithkline Biologicals Sa Methods of inducing an immune response
CA3132601A1 (en) 2019-03-05 2020-09-10 Glaxosmithkline Biologicals Sa Hepatitis b immunisation regimen and compositions
US20230201334A1 (en) 2019-07-24 2023-06-29 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
CA3202549A1 (en) 2020-12-02 2022-06-09 Glaxosmithkline Biologicals Sa Novel antigens
WO2022161598A1 (en) 2021-01-26 2022-08-04 Eth Zurich Antibodies broadly targeting coronaviruses and uses thereof
WO2022162012A2 (en) 2021-01-26 2022-08-04 Eth Zurich Antibodies broadly targeting coronaviruses and uses thereof
WO2023114727A1 (en) 2021-12-13 2023-06-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bacteriophage lambda-vaccine system
WO2023144665A1 (en) 2022-01-28 2023-08-03 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
WO2024133160A1 (en) 2022-12-19 2024-06-27 Glaxosmithkline Biologicals Sa Hepatitis b compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8501582A (nl) * 1985-02-12 1986-09-01 Philips Nv Videosignaalverwerkingsschakeling voor de verwerking van een geinterlinieerd videosignaal.
GR860379B (en) * 1985-02-22 1986-06-11 Akzo Nv Novel disaccharide and trisaccharide derivatives of the lipid a type
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5158939A (en) * 1989-07-21 1992-10-27 Wisconsin Alumni Research Foundation Method of stimulating the immune systems of animals and compositions useful therefor
JPH06206893A (ja) * 1992-09-07 1994-07-26 Suntory Ltd 新規なジサッカライド誘導体

Also Published As

Publication number Publication date
GR3034872T3 (en) 2001-02-28
ES2149340T3 (es) 2000-11-01
EP0729473B1 (en) 2000-08-23
RU2154068C2 (ru) 2000-08-10
CN1137799A (zh) 1996-12-11
JP3967769B2 (ja) 2007-08-29
HU9601312D0 (en) 1996-07-29
CA2175375A1 (en) 1995-05-26
PL314494A1 (en) 1996-09-16
KR100355470B1 (ko) 2003-02-17
DE69425671D1 (de) 2000-09-28
AU1219495A (en) 1995-06-06
HU219810B (hu) 2001-08-28
US6005099A (en) 1999-12-21
SK281944B6 (sk) 2001-09-11
JPH09505071A (ja) 1997-05-20
AU700485B2 (en) 1999-01-07
ATE195740T1 (de) 2000-09-15
EP0729473A1 (en) 1996-09-04
CN1055093C (zh) 2000-08-02
WO1995014026A1 (en) 1995-05-26
CA2175375C (en) 2010-01-05
BR9408071A (pt) 1996-12-24
CZ141896A3 (en) 1996-10-16
HUT74738A (en) 1997-02-28
SK61396A3 (en) 1996-11-06
PT729473E (pt) 2001-02-28
CZ290331B6 (cs) 2002-07-17
SI0729473T1 (en) 2001-02-28
DE69425671T2 (de) 2001-04-19
RO115731B1 (ro) 2000-05-30
PL181241B1 (pl) 2001-06-29

Similar Documents

Publication Publication Date Title
DK0729473T3 (da) Glucosamin-disaccharider, fremgangsmåde til deres fremstilling farmaceutisk sammensætning deraf og deres anvendelse
UA70298A (uk) Похідні с-4"-заміщених макролідів, спосіб їх одержання, проміжні сполуки, фармацевтична композиція та спосіб лікування бактеріальної інфекції або протозойної інфекції
PL314188A1 (en) Novel derivatives of benzoguanidine, method of obtaining them and their application in pharmaceutical compositions
BR9711135A (pt) Composto composi-Æo farmac-utica utiliza-Æo de um composto e processos para prepara-Æo de um composto e para inibi-Æo de Äxido-equaleno ciclase num animal de sangue quente requerendo um tal tratamento
ATE255589T1 (de) Kristallin form i von clarithromycin
DK0712396T3 (da) Substituerede azadioxacycloalkener og deres anvendelse som fungicider
CA2387356A1 (en) Crystal form 0 and form i of clarithromycin and uses thereof
HUT72436A (en) Process for the production of imidazopyridines and pharmaceutical compositions containing them and which are suitable for treating gastro-intestinal diseases
BG104644A (en) Novel macrolides
PL315973A1 (en) Compositions containing micronised nebivolol
IL113160A (en) Lipopeptide a1437 derivatives a process for their preparation and pharmaceutical compositions containing them
YU40900A (sh) Novi derivati eritromicina
HUT60713A (en) Process for producing pharmaceutical compositions suitable for treating hiv infections and for producing their active ingredients
MY122353A (en) 13-membered azalides and their use as antibiotic agents
CA2123232A1 (fr) Compositions pharmaceutiques a base d'ebastine ou de ses analogues
ES8301244A1 (es) Procedimiento para la obtencion de derivados de sisomicina.
UA41871C2 (uk) Похідні еритроміцину, спосіб їх одержання та фармацевтична композиція на їх основі
BR9610175A (pt) Composto processo de preparação do composto composição farmacêutica e utilização do composto
AP9801235A0 (en) Erythromycin derivatives.
GR3025050T3 (en) Etoposide derivatives, process for their preparation, their use as a drug and in the preparation of a drug for treating cancer.
IE43125L (en) Aminoglycoside derivative
KR870008910A (ko) 돼지 이질의 예방 및 치료제
UA48982C2 (uk) Поліморфи проліків тровафлоксацину, спосіб їх отримання, спосіб лікування бактеріальної інфекції і фармацевтична композиція
IL110025A0 (en) Phosphonosuccinic acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them